OrthoPediatrics Corp. (NASDAQ:KIDS) CFO Sells $160,172.98 in Stock

OrthoPediatrics Corp. (NASDAQ:KIDS) CFO Fred Hite sold 6,443 shares of the firm’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total value of $160,172.98. Following the transaction, the chief financial officer now owns 207,989 shares of the company’s stock, valued at $5,170,606.54. This trade represents a 3.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

OrthoPediatrics Price Performance

KIDS stock traded up $0.46 during midday trading on Tuesday, reaching $25.42. 138,044 shares of the company’s stock traded hands, compared to its average volume of 162,840. The company has a 50-day simple moving average of $24.74 and a two-hundred day simple moving average of $25.62. OrthoPediatrics Corp. has a 1-year low of $21.02 and a 1-year high of $35.99. The company has a market cap of $617.38 million, a price-to-earnings ratio of -20.67 and a beta of 1.22. The company has a quick ratio of 3.68, a current ratio of 7.17 and a debt-to-equity ratio of 0.19.

OrthoPediatrics (NASDAQ:KIDS) last released its quarterly earnings results on Tuesday, March 4th. The company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. OrthoPediatrics had a negative return on equity of 5.78% and a negative net margin of 15.00%. The firm had revenue of $52.67 million during the quarter, compared to analysts’ expectations of $51.16 million. During the same period last year, the firm posted ($0.23) EPS. On average, analysts anticipate that OrthoPediatrics Corp. will post -0.93 earnings per share for the current year.

Institutional Investors Weigh In On OrthoPediatrics

Several hedge funds and other institutional investors have recently made changes to their positions in KIDS. Quarry LP acquired a new stake in shares of OrthoPediatrics in the 3rd quarter valued at $25,000. R Squared Ltd acquired a new stake in shares of OrthoPediatrics in the 4th quarter valued at $48,000. KLP Kapitalforvaltning AS bought a new position in shares of OrthoPediatrics in the 4th quarter worth $79,000. BNP Paribas Financial Markets boosted its position in shares of OrthoPediatrics by 125.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,471 shares of the company’s stock worth $94,000 after purchasing an additional 1,929 shares during the last quarter. Finally, Quantbot Technologies LP boosted its position in shares of OrthoPediatrics by 42.2% in the 3rd quarter. Quantbot Technologies LP now owns 5,773 shares of the company’s stock worth $157,000 after purchasing an additional 1,712 shares during the last quarter. 69.05% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms recently commented on KIDS. Truist Financial cut their target price on OrthoPediatrics from $28.00 to $25.00 and set a “hold” rating for the company in a research report on Wednesday, December 18th. Stifel Nicolaus cut their target price on OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, March 5th. Finally, Needham & Company LLC restated a “buy” rating and set a $42.00 target price on shares of OrthoPediatrics in a research report on Wednesday, March 5th.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.